Excision BioTherapeutics, headquartered in San Francisco, specializes in developing CRISPR-based therapies to cure viral infectious diseases. Leveraging gene-editing technology, the company aims to transform treatment options in virology. With a focus on innovative biotherapeutics, Excision BioTherapeutics is advancing novel approaches to combat viral infections.

‌